Mavacamten dosing considerations in special patient populations¹

No dose adjustment to the standard dose and titration scheme is required for patients aged 65 years and older.

No dose adjustment to the standard dose and titration scheme is required for patients with mild (estimated glomerular filtration rate [eGFR] 60–89 mL/min/1.73m²) to moderate (eGFR 30–59 mL/min/1.73m²) renal impairment. No dose recommendation can be made for patients with severe (eGFR <30 mL/min/1.73m²) renal impairment because mavacamten has not been studied in patients with severe renal impairment.

The mavacamten starting dose should be 2.5 mg in all patients with mild (Child-Pugh class A) and moderate (Child-Pugh class B) hepatic impairment since mavacamten exposure is likely to be increased. No dose recommendation can be made for patients with severe hepatic impairment (Child-Pugh class C) because mavacamten has not been studied in patients with severe hepatic impairment.

The safety and efficacy of mavacamten in children and adolescents below 18 years have not been established. No data are available. Mavacamten should not be used in children less than 12 years because of potential safety concerns.